Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...